Summary & Overview
HCPCS Level II J9020: Injection, asparaginase, 10,000 units
Headline: HCPCS Level II code J9020 covers asparaginase injections used in cancer chemotherapy
Lead: HCPCS Level II code J9020 denotes a 10,000-unit injection of asparaginase, a chemotherapeutic agent commonly used in the treatment of acute leukemias. The code identifies the drug product for billing and administrative workflows and is relevant across outpatient infusion centers and physician offices nationwide.
What the code represents and why it matters: J9020 specifies the administered drug and dose unit for asparaginase, enabling consistent reporting of chemotherapy drug delivery. Accurate coding supports clinical documentation, claim processing, and pharmacy inventory control, and informs payer coverage and prior authorization processes.
Key payers covered: The analysis references national commercial payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
What readers will learn: The publication provides clinical context for asparaginase use in chemotherapy, compares related HCPCS drug codes, and flags common billing considerations such as site-of-service implications and service-line documentation. It summarizes typical settings where J9020 is billed (outpatient infusion and office-based injections) and outlines associated clinical indications tied to acute leukemia treatment.
Limitations: Data not available in the input for specific utilization rates, reimbursement benchmarks, and payer policy details. These items are noted where applicable.
Billing Code Overview
HCPCS Level II code J9020 represents Injection, asparaginase, not otherwise specified, 10,000 units. This code is used to report administration of asparaginase as a chemotherapeutic agent.
Service Type: Chemotherapy drug administration.
Typical Site of Service: Infusion or injection setting, such as an outpatient facility or physician office.
Clinical & Coding Specifications
Clinical Context
A patient with acute lymphoblastic leukemia is scheduled for chemotherapy management that includes an intramuscular or intravenous injection of asparaginase. The service is delivered in an outpatient infusion center or office-based injection setting. The clinical workflow includes verification of the diagnosis and treatment plan, informed consent, drug preparation by pharmacy, administration by an oncology nurse, post-injection monitoring for hypersensitivity or pancreatitis, documentation of lot number and units administered, and billing using HCPCS Level II code J9020 for asparaginase in 10,000-unit increments.
Coding Specifications
-
Modifiers:
-
JW— Drug amount discarded/not administered to any patient: used when a portion of the dispensed asparaginase dose is discarded and the discarded amount must be reported separately from the amount administered. -
59— Distinct Procedural Service: used when the injection of asparaginase is a separate and distinct service from other procedures or services performed on the same day (e.g., separate encounter distinct from an infusion visit), and documentation supports a separate procedural service. -
Provider taxonomies and specialties:
-
207RH0003X— Hematology & Oncology Physician -
207RX0202X— Medical Oncology Physician -
208D00000X— General Practice Physician
Related Diagnoses
C91.00— Acute lymphoblastic leukemia, not having achieved remission
Clinical relevance: Indicates active disease status for which asparaginase treatment (J9020) may be part of induction or salvage chemotherapy.
C91.01— Acute lymphoblastic leukemia, in remission
Clinical relevance: Indicates remission status; asparaginase may be used in consolidation or maintenance protocols depending on the regimen.
C91.02— Acute lymphoblastic leukemia, in relapse
Clinical relevance: Indicates disease recurrence; asparaginase may be part of a relapse-directed chemotherapy plan.
C92.00— Acute myeloblastic leukemia, not having achieved remission
Clinical relevance: Represents an acute myelogenous leukemia diagnosis where asparaginase might be used in select protocols or clinical scenarios.
C92.01— Acute myeloblastic leukemia, in remission
Clinical relevance: Represents remission status of acute myeloblastic leukemia; billing with J9020 would reflect treatment phases or maintenance when asparaginase is indicated.
Related Codes
J9000— Injection, doxorubicin hydrochloride, 10 mg
Explanation: J9000 is another chemotherapy drug HCPCS Level II code; it may appear on the same patient’s record when different chemotherapeutic agents are administered during the course of treatment, though not typically given concurrently with J9020 for the same indication.
J9027— Injection, clofarabine, 1 mg
Explanation: J9027 is an alternative chemotherapeutic agent’s HCPCS Level II code; it may be billed during different treatment phases or as an alternative regimen in hematologic malignancy management. Both J9027 and J9000 can appear in the same chemotherapy treatment plan depending on regimen selection.
National Reimbursement Benchmarks
National mean rates for HCPCS Level II code J9020 show that Medicare is lower than the average commercial benchmark (BUCA). BUCA (average commercial) posts a mean of $69.82 while Medicare data is not available in the input; among commercial payers, UnitedHealthcare has the highest mean at $83.64 and Aetna the lowest at $33.81.
Rate dispersion varies by payer. Cigna Health and Blue Cross Blue Shield are relatively tight (P75–P25 ranges of 2 and 4 respectively), while BUCA and Aetna show wider dispersion (ranges of 16.5 and 22 respectively). UnitedHealthcare has a moderate dispersion (range of 8). The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.